medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 1

<< Back Next >>

Rev Mex Urol 2024; 84 (1)

Sensitivity and specificity of prostate health index (PHI), for the scrutiny of prostate cancer, avoiding the practice of unnecessary biopsies

Ángeles-Gómez BM, Castrejón-Delgado L

Language: Spanish
References: 25
Page: 1-9
PDF size: 161.30 Kb.


ABSTRACT

Objective: To determine the sensitivity and specificity of the prostate health index (PHI) for prostate cancer screening in Mexican population with total prostate antigen (PSA) levels greater than 4ng/mL, in a second level hospital.
Method: An exploratory, cross-sectional, retrospective, diagnostic test-type study was performed in a second level hospital. Data were collected from 84 patients who underwent prostate biopsy, selected through the review of laboratory studies. The sensitivity, specificity, positive and negative predictive values, ROC curve and the area under the curve (AUC) were measured.
Results: The sensitivity and specificity of the PHI obtained was 82 % and 84 % respectively. We considered 43 points as the optimal cutoff given by the ROC curve, with an area under the curve of 0.930; likewise, the positive predictive value was 72 % and the negative predictive value was 90%.
Limitations: The main limitation is the sample size.
Originality: It is necessary the application of new biomarkers as a screening method with a greater reliability for the diagnosis of prostate cancer to avoid the unnecessary practice of biopsies in Mexican population.
Conclusions: The study demonstrated a good prostate health index (PHI) sensitivity and specificity.


REFERENCES

  1. Leslie SW, Soon-Sutton TL, R I A, Sajjad H,Skelton WP. Prostate Cancer. In: StatPearls.Treasure Island (FL): StatPearls Publishing; 2024.

  2. Islas Pérez LÁ, Martínez Reséndiz JI, RuizHernández A, Ruvalcaba Ledezma JC,Benítez Medina A, Beltran Rodríguez MG, etal. Epidemiología del cáncer de próstata, susdeterminantes y prevención. Journal of Negativeand No Positive Results. 2020;5(9): 1010–1022.https://dx.doi.org/10.19230/jonnpr.3686.

  3. Castillejos-Molina RA, Gabilondo-NavarroFB, Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Públicade México. 2016;58(2): 279–284. https://doi.org/10.21149/spm.v58i2.7797

  4. Jara Rascón J, Subirá Ríos D, LLedó García E,Martínez Salamanca JI, Moncada IribarrenI, Hernández Fernández C. Evaluación delantígeno especifico prostático (PSA) ajustado alvolumen de la zona transicional en la deteccióndel cáncer de próstata. Actas UrológicasEspañolas. 2005;29(5): 485–492.

  5. Morejón WV, Sena BJ, Vega YP, Águila Yde la CR, García IC. Antígeno prostáticoespecífico como predictor del diagnóstico deadenocarcinoma prostático. Revista Finlay.2015;5(4): 221–227.

  6. Gelpi-Méndez JA, Gómez-Fernández E,Martín-Barallat J, Cortés-Arcas MV, Monsonis-Artero JV, Calvo-Mora A. Valores de referenciadel antígeno prostático específico (PSA) en63.926 trabajadores sin síntomas prostáticos queparticiparon en el cribado de cáncer de próstatadesarrollado por la Sociedad de Prevenciónde Ibermutuamur durante el año 2006. ActasUrológicas Españolas. 2010;34(8): 669–676.

  7. Ferro M, De Cobelli O, Lucarelli G, Porreca A,Busetto GM, Cantiello F, et al. Beyond PSA: TheRole of Prostate Health Index (phi). InternationalJournal of Molecular Sciences. 2020;21(4): 1184.https://doi.org/10.3390/ijms21041184.

  8. Zegarra-Montes L, Sarria-Bardales G,Martínez-Perez D, Del-Castillo-Pacora R,Dyer-Velarde-Álvarez R, Trelles-De-BelaundeM. Viabilidad y seguridad de la biopsia prostáticatransperineal en la era de fusión de imágenespor resonancia magnética cognitiva/ultrasonidoen la detección del cáncer. Acta Médica Peruana.2022;39(2). https://doi.org/10.35663/amp.2022.392.2331.

  9. Lepor A, Catalona WJ, Loeb S. The ProstateHealth Index. Urologic Clinics of North America.2016;43(1): 1–6. https://doi.org/10.1016/j.ucl.2015.08.001.

  10. Nordström T, Vickers A, Assel M, Lilja H,Grönberg H, Eklund M. Comparison Betweenthe Four-kallikrein Panel and Prostate HealthIndex for Predicting Prostate Cancer. EuropeanUrology. 2015;68(1): 139–146. https://doi.org/10.1016/j.eururo.2014.08.010.

  11. Yáñez-Castillo YM, Melgarejo-Segura MT,Funes-Padilla C, Folgueral-Corral ME, García-Larios JV, Arrabal-Polo MA, et al. Prostatehealth index (PHI) as an accurate prostatecancer predictor. Journal of Cancer Research andClinical Oncology. 2023;149(11): 9329–9335.https://doi.org/10.1007/s00432-023-04860-6.

  12. Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, et al. Accuracy of theprostate health index versus the urinary prostatecancer antigen 3 score to predict overall andsignificant prostate cancer at initial biopsy: PHIvs. PCA-3 to Detect Overall and SignificantProstate Cancer. The Prostate. 2015;75(1): 103–111. https://doi.org/10.1002/pros.22898.

  13. Saini S. PSA and beyond: alternative prostatecancer biomarkers. Cellular Oncology.2016;39(2): 97–106. https://doi.org/10.1007/s13402-016-0268-6.

  14. Farha MW, Salami SS. Biomarkersfor prostate cancer detection and riskstratification. Therapeutic Advances in Urology.2022;14: 175628722211039. https://doi.org/10.1177/17562872221103988.

  15. Abrate A, Lughezzani G, Gadda GM, Lista G,Kinzikeeva E, Fossati N, et al. Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSAand Prostate Health Index) for the Detectionof Prostate Cancer: A Review of the Literature.Korean Journal of Urology. 2014;55(7): 436.https://doi.org/10.4111/kju.2014.55.7.436.

  16. De La Calle C, Patil D, Wei JT, Scherr DS, SokollL, Chan DW, et al. Multicenter Evaluation ofthe Prostate Health Index to Detect AggressiveProstate Cancer in Biopsy Naïve Men. Journalof Urology. 2015;194(1): 65–72. https://doi.org/10.1016/j.juro.2015.01.091.

  17. Chiu ST, Cheng YT, Pu YS, Lu YC, Hong JH,Chung SD, et al. Prostate Health Index DensityOutperforms Prostate Health Index in ClinicallySignificant Prostate Cancer Detection. Frontiersin Oncology. 2021;11: 772182. https://doi.org/10.3389/fonc.2021.772182.

  18. Le BV, Griffin CR, Loeb S, Carvalhal GF, KanD, Baumann NA, et al. [-2]Proenzyme ProstateSpecific Antigen is More Accurate Than Total andFree Prostate Specific Antigen in DifferentiatingProstate Cancer From Benign Disease in aProspective Prostate Cancer Screening Study.Journal of Urology. 2010;183(4): 1355–1359.https://doi.org/10.1016/j.juro.2009.12.056.

  19. Stephan C, Vincendeau S, Houlgatte A,Cammann H, Jung K, Semjonow A. MulticenterEvaluation of [−2]Proprostate-SpecificAntigen and the Prostate Health Index forDetecting Prostate Cancer. Clinical Chemistry.

  20. 2013;59(1): 306–314. https://doi.org/10.1373/clinchem.2012.195784.20. Loeb S, Sokoll LJ, Broyles DL, Bangma CH,Van Schaik RHN, Klee GG, et al. ProspectiveMulticenter Evaluation of the Beckman CoulterProstate Health Index Using WHO Calibration.Journal of Urology. 2013;189(5): 1702–1706.https://doi.org/10.1016/j.juro.2012.11.149.

  21. Park H, Lee SW, Song G, Kang TW, Jung JH,Chung HC, et al. Diagnostic Performance of%[-2]proPSA and Prostate Health Index forProstate Cancer: Prospective, Multi-institutionalStudy. Journal of Korean Medical Science.2018;33(11): e94. https://doi.org/10.3346/jkms.2018.33.e94.

  22. Lazzeri M, Haese A, Abrate A, De La TailleA, Redorta JP, McNicholas T, et al. Clinicalperformance of serum prostate-specificantigen isoform [-2] proPSA ( p2PSA ) and itsderivatives, % p2PSA and the prostate healthindex ( PHI ), in men with a family history ofprostate cancer: results from a multicentre European study, the PROMEtheuS project. BJUInternational. 2013;112(3): 313–321. https://doi.org/10.1111/bju.12217.

  23. Filella X, Giménez N. Evaluation of [−2]proPSA and Prostate Health Index (phi) forthe detection of prostate cancer: a systematicreview and meta-analysis. Clinical Chemistry andLaboratory Medicine (CCLM). 2013;51(4): 729–739. https://doi.org/10.1515/cclm-2012-0410.

  24. Agnello L, Vidali M, Giglio RV, Gambino CM,Ciaccio AM, Lo Sasso B, et al. Prostate healthindex (PHI) as a reliable biomarker for prostatecancer: a systematic review and meta-analysis.Clinical Chemistry and Laboratory Medicine(CCLM). 2022;60(8): 1261–1277. https://doi.org/10.1515/cclm-2022-0354.

  25. Lopes Vendrami C, McCarthy RJ, Chatterjee A,Casalino D, Schaeffer EM, Catalona WJ, et al.The Utility of Prostate Specific Antigen Density,Prostate Health Index, and Prostate HealthIndex Density in Predicting Positive ProstateBiopsy Outcome is Dependent on the ProstateBiopsy Methods. Urology. 2019;129: 153-159.https://doi.org/10.1016/j.urology.2019.03.018.




2020     |     www.medigraphic.com